Dipal Doshi - Entrada Therapeutics CEO Director
| TRDA Stock | USD 19.37 0.33 1.73% |
CEO
Dipal Doshi is CEO Director of Entrada Therapeutics
| Age | 48 |
| Address | One Design Center Place, Boston, MA, United States, 02210 |
| Phone | 857 520 9158 |
| Web | https://www.entradatx.com |
Latest Insider Transactions
Dipal Doshi Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dipal Doshi against Entrada Therapeutics stock is an integral part of due diligence when investing in Entrada Therapeutics. Dipal Doshi insider activity provides valuable insight into whether Entrada Therapeutics is net buyers or sellers over its current business cycle. Note, Entrada Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Entrada Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dipal Doshi over three months ago Disposition of 1600 shares by Dipal Doshi of Entrada Therapeutics at 17.8108 subject to Rule 16b-3 | ||
Dipal Doshi over three months ago Disposition of 1000 shares by Dipal Doshi of Entrada Therapeutics at 16.1736 subject to Rule 16b-3 | ||
Dipal Doshi over six months ago Disposition of 1200 shares by Dipal Doshi of Entrada Therapeutics at 15.1076 subject to Rule 16b-3 | ||
Dipal Doshi over six months ago Disposition of 1000 shares by Dipal Doshi of Entrada Therapeutics at 15.0 subject to Rule 16b-3 |
Entrada Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.0695 % which means that it generated a profit of $0.0695 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1642 %, meaning that it created $0.1642 on every $100 dollars invested by stockholders. Entrada Therapeutics' management efficiency ratios could be used to measure how well Entrada Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2024, Return On Tangible Assets is expected to decline to -0.01. In addition to that, Return On Capital Employed is expected to decline to -0.01. At present, Entrada Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 7.1 M, whereas Total Assets are forecasted to decline to about 239.5 M.Similar Executives
| Found 8 records | CEO Age | ||
| Kevin Koch | Edgewise Therapeutics | 64 | |
| Scott Struthers | Crinetics Pharmaceuticals | 61 | |
| Carole MD | Larimar Therapeutics | 65 | |
| Nadim Ahmed | Cullinan Oncology LLC | 56 | |
| Markus MD | Monte Rosa Therapeutics | 53 | |
| BAO BCh | Eliem Therapeutics | 48 | |
| Ivana JD | Vigil Neuroscience | 57 | |
| Esq JD | Disc Medicine | 53 | |
Management Performance
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0695 |
Entrada Therapeutics Leadership Team
Elected by the shareholders, the Entrada Therapeutics' board of directors comprises two types of representatives: Entrada Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Entrada. The board's role is to monitor Entrada Therapeutics' management team and ensure that shareholders' interests are well served. Entrada Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Entrada Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dipal Doshi, CEO Director | ||
| Kory CPA, CFO Treasurer | ||
| Kerry MS, Senior People | ||
| Jared JD, General Counsel | ||
| Nathan Dowden, Chief Officer | ||
| Natarajan Sethuraman, President Development | ||
| Karla MacDonald, Chief Officer | ||
| Kevin Healy, Senior Affairs | ||
| MBA MD, Chief Officer |
Entrada Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Entrada Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0695 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | (1.11) % | ||||
| Current Valuation | 324.45 M | ||||
| Shares Outstanding | 37.42 M | ||||
| Shares Owned By Insiders | 12.82 % | ||||
| Shares Owned By Institutions | 80.83 % | ||||
| Number Of Shares Shorted | 1.66 M | ||||
| Price To Book | 1.69 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Entrada Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entrada Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entrada Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entrada Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Entrada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.